Related references
Note: Only part of the references are listed.Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Massimiliano Mazzone et al.
CELL (2009)
Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target
Stina Haggstrom Rudolfsson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Low Stroma Androgen Receptor Level in Normal and Tumor Prostate Tissue Is Related to Poor Outcome in Prostate Cancer Patients
Pernilla Wikstrom et al.
PROSTATE (2009)
Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype
Karl T. Butterworth et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Exploring vascular dysfunction caused by tirapazamine
Lynsey A. Huxham et al.
MICROVASCULAR RESEARCH (2008)
Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1 alpha
Stina Haggstrom Rudolfsson et al.
JOURNAL OF ENDOCRINOLOGY (2008)
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model
Anna Johansson et al.
PROSTATE (2007)
Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment
Sofia Halin et al.
PROSTATE (2007)
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition
Peter Hammarsten et al.
CLINICAL CANCER RESEARCH (2006)
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: A well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
U Emmenegger et al.
CANCER RESEARCH (2006)
Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats
A Johansson et al.
ENDOCRINOLOGY (2005)
Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment
N Ohlson et al.
PROSTATE (2005)
Mild sustained and intermittent hypoxia induce apoptosis in PC-12 cells via different mechanisms
E Gozal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy
P Wikström et al.
PROSTATE (2005)
Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration
GI Frost et al.
MICROVASCULAR RESEARCH (2005)
Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer
C Parker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: A promising therapeutic approach
B Nicholson et al.
CLINICAL CANCER RESEARCH (2004)
Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis
H Zhong et al.
CANCER DETECTION AND PREVENTION (2004)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Direct regulation of prostate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo
Y Shibata et al.
ENDOCRINOLOGY (2004)
Hypoxia-inducible factors and hypoxic cell death in tumour physiology
AL Bacon et al.
ANNALS OF MEDICINE (2004)
Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice
IF Lissbrant et al.
PROSTATE (2004)
The hypoxic tumour microenvironment and metastatic progression
P Subarsky et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells
MA Ghafar et al.
PROSTATE (2003)
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
JL Yu et al.
DIFFERENTIATION (2002)
Hypoxic prostate/muscle Po2 ratio predicts for biochemical failure in patients with prostate cancer:: Preliminary findings
B Movsas et al.
UROLOGY (2002)
Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer
ME Gleave et al.
INVESTIGATIONAL NEW DRUGS (2002)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer
D Cvetkovic et al.
UROLOGY (2001)
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
RJ Stewart et al.
JOURNAL OF UROLOGY (2001)
Semiquantitative immunohistochemical analysis for hypoxia in human tumors
JA Raleigh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
RS Kerbel et al.
CANCER AND METASTASIS REVIEWS (2001)
Share Paper
